Cytel Webinar – US Drug Pricing Reform: Potential Impact of Pharma HEOR Evidence Generation – September 8th
September 1, 2022
With the passage of the Inflation Reduction Act by the US, pharma and biotech companies have to reevaluate their pricing strategies. In a Cytel webinar taking place on September 8th, Anna Forsythe of Cytel and Dr. Edmund Pezalla of Bioconsult discuss how these reforms will influence the field and how real-world evidence and health economics and outcomes research (HEOR) based research can help companies prepare.
According to Cytel, learning points include:
“Summary of reform and potential impact to pharma industry
Types of drugs that may be impacted by the reform
Impact of reform for new and existing drugs
How private payers may be impacted by this reform?
Scope for pharma negotiation based on value-based pricing and supporting HEOR evidence?
How pharma companies can prepare”
To register, click here.
(Source: Cytel, September 1st, 2022)